Physician profile
Binitha Joseph
NPI 1881893139
$471.61
in general payments reported to CMS, 2019-2025
12 companies · $16.13 in 2025
The $16.13 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $15.01 · 2021: $27.72 · 2022: $57.17 · 2023: $128 · 2024: $94.74 · 2025: $16.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $87.78 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $81.32 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $70.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $53.44 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $32.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.67 | 2019-2020 | |
| Tactile Systems Technology INC | $27.19 | 2023 | Entre Plus, Flexitouch Plus |
| Abbvie INC. | $25.12 | 2023 | |
| Glaxosmithkline, LLC. | $19.18 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Paratek Pharmaceuticals, INC. | $16.13 | 2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $15.05 | 2019 | |
| Abbott Laboratories | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binitha Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.